NCT03740165 2025-10-22KEYLYNK-001Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,367 enrolled 29 charts
NCT00391118 2020-10-19Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")Eli Lilly and CompanyPhase 2 Completed153 enrolled 20 charts
NCT01015118 2017-12-07LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian CancerBoehringer IngelheimPhase 3 Completed1,366 enrolled 17 charts
NCT00191646 2011-03-04An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior ChemotherapyEli Lilly and CompanyPhase 3 Completed919 enrolled 18 charts
NCT00063401 2010-04-08Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube CancerEli Lilly and CompanyPhase 2 Completed39 enrolled